Current and Emerging Biologics for Ulcerative Colitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sung Chul | - |
dc.contributor.author | Jeen, Yoon Tae | - |
dc.date.accessioned | 2021-09-04T20:19:29Z | - |
dc.date.available | 2021-09-04T20:19:29Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-01 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94711 | - |
dc.description.abstract | Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.subject | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject | MAINTENANCE THERAPY | - |
dc.subject | CROHNS-DISEASE | - |
dc.subject | INFLIXIMAB | - |
dc.subject | INDUCTION | - |
dc.subject | EFFICACY | - |
dc.subject | ETROLIZUMAB | - |
dc.subject | MANAGEMENT | - |
dc.subject | REMISSION | - |
dc.subject | PLACEBO | - |
dc.title | Current and Emerging Biologics for Ulcerative Colitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeen, Yoon Tae | - |
dc.identifier.doi | 10.5009/gnl14226 | - |
dc.identifier.scopusid | 2-s2.0-84919385044 | - |
dc.identifier.wosid | 000347142100004 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.9, no.1, pp.18 - 27 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 9 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18 | - |
dc.citation.endPage | 27 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001956814 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ETROLIZUMAB | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordAuthor | Biological therapies | - |
dc.subject.keywordAuthor | Ulcerative colitis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.